AstraZeneca consolidates its drug development work

03/19/2013 | Reuters · USA Today

AstraZeneca plans to restructure its research and development operations to bring together drug development activities in three major facilities in the U.S., England and Sweden. A Gaithersburg, Md., facility will become the main hub for biotech research. The changes, meant to cut costs and increase productivity, will eliminate about 1,600 positions.

View Full Article in:

Reuters · USA Today

Published in Brief:

SmartBrief Job Listings for Health Care